27 related articles for article (PubMed ID: 11853610)
1. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
Saito H; Suzuki N
Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
[TBL] [Abstract][Full Text] [Related]
3. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
[TBL] [Abstract][Full Text] [Related]
4. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
5. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
6. Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis.
Tsuda T; Mochizuki M; Wakasa H
J Gastroenterol; 1995 Nov; 30 Suppl 8():30-2. PubMed ID: 8563883
[TBL] [Abstract][Full Text] [Related]
7. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction.
Stratton MR; Fisher C; Gusterson BA; Cooper CS
Cancer Res; 1989 Nov; 49(22):6324-7. PubMed ID: 2680062
[TBL] [Abstract][Full Text] [Related]
8. [Point mutations of N-ras oncogene and abnormal expression of rasp21, p53 proteins in orbital rhabdomyosarcoma].
Zhang H; Song G; Zhang S; Chang J; Zhang W; Yu H
Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):267-9, 16. PubMed ID: 11853610
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Role of Cytogenetics in the Diagnosis of Orbital Rhabdomyosarcoma.
Cortes Barrantes P; Jakobiec FA; Dryja TP
Semin Ophthalmol; 2019; 34(4):243-251. PubMed ID: 31146616
[TBL] [Abstract][Full Text] [Related]
10. Multimodality management of orbital rhabdomyosarcoma.
Weichselbaum RR; Cassady JR; Albert DM; Gonder JR
Int Ophthalmol Clin; 1980; 20(2):247-59. PubMed ID: 6995390
[No Abstract] [Full Text] [Related]
11. Cooperation of p53 mutations with other oncogenic alterations in cancer.
Girardini JE; Walerych D; Del Sal G
Subcell Biochem; 2014; 85():41-70. PubMed ID: 25201188
[TBL] [Abstract][Full Text] [Related]
12. Potential immunogenicity of oncogene and tumor suppressor gene products.
Melief CJ; Kast WM
Curr Opin Immunol; 1993 Oct; 5(5):709-13. PubMed ID: 8240732
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
